electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
December 17, 2024 16:05 ET
|
electroCore, Inc.
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at...
FemPulse Receives FDA IDE Approval for the Pivotal Clinical Trial of its Wearable Bioelectronic Device for Overactive Bladder in Women
December 11, 2024 15:18 ET
|
FemPulse
SAN FRANCISO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II...
Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by UKCA for NHS & Private UK Clinics
December 05, 2024 04:02 ET
|
Magstim EGI
UKCA Approves Magstim Horizon Inspire TMS for NHS & Private UK Clinics. UK Made System for Patient Treatment of MDD, OCD and Decreasing Anxiety.
Curonix Foundational Clinical Data Published Within the American Society of Interventional Pain Physicians (ASIPP) Peripheral Nerve Stimulation Guidelines for the Management of Chronic Pain
December 04, 2024 08:00 ET
|
Curonix LLC
Curonix Foundational Clinical Data Published Within the American Society of Interventional Pain Physicians (ASIPP) Peripheral Nerve Stimulation Guidelines
FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression
November 12, 2024 08:11 ET
|
Magstim EGI
FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression
Neuromodulation Devices Research Report 2024 - Global Market Insights, Competitive Landscape, and Forecasts to 2030
July 16, 2024 08:00 ET
|
Research and Markets
Dublin, July 16, 2024 (GLOBE NEWSWIRE) -- The "Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System
July 09, 2024 08:00 ET
|
Curonix LLC
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System.
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
June 10, 2024 03:00 ET
|
Amber Therapeutics
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique...
Distributor Orders Nexstim NBS System 5 for European Hospital
June 10, 2024 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 10 June 2024 at 9 AM (EEST) Distributor Orders Nexstim NBS System 5 for European Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS...
Sisäpiiritieto: Nexstim Oyj tiedottaa suunnitellusta yhteistyöstä Sinaptica Therapeutics, Inc:n kanssa Alzheimerin taudin hoidon alalla
June 07, 2024 02:00 ET
|
Nexstim Oyj
Yhtiötiedote, Helsinki, 07.06.2024 klo. 9.00 (EEST) Sisäpiiritieto: Nexstim Oyj tiedottaa suunnitellusta yhteistyöstä Sinaptica Therapeutics, Inc:n kanssa Alzheimerin taudin hoidon alalla Nexstim...